Next Article in Journal
The Positive Effect of 6-Gingerol on High-Fat Diet and Streptozotocin-Induced Prediabetic Mice: Potential Pathways and Underlying Mechanisms
Next Article in Special Issue
Association of NAFLD with FGF21 Polygenic Hazard Score, and Its Interaction with Protein Intake Level in Korean Adults
Previous Article in Journal
Association between Consumption of Dietary Supplements and Chronic Kidney Disease Prevalence: Results of the Korean Nationwide Population-Based Survey
Previous Article in Special Issue
Drinking Habits and Physical Activity Interact and Attenuate Obesity Predisposition of TMEM18 Polymorphisms Carriers
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Nutrients
Volume 15
Issue 4
10.3390/nu15040823
nutrients-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Association between Single Nucleotide Polymorphisms Related to Vitamin D Metabolism and the Risk of Developing Asthma

by
Susana Rojo-Tolosa
1,*,
Laura Elena Pineda-Lancheros
2,*,
José María Gálvez-Navas
3,4,*,
José Antonio Sánchez-Martínez
1,
María Victoria González-Gutiérrez
1,
Andrea Fernández-Alonso
2,
Concepción Morales-García
1,†,
Alberto Jiménez-Morales
2,† and
Cristina Pérez-Ramírez
2,3,†
1
Respiratory Medicine Department, University Hospital Virgen de las Nieves, 18014 Granada, Spain
2
Pharmacogenetics Unit, Pharmacy Service, University Hospital Virgen de las Nieves, 18014 Granada, Spain
3
Biomedical Research Center, Department of Biochemistry and Molecular Biology II, Institute of Nutrition and Food Technology “José Mataix”, University of Granada, Avda. del Conocimiento s/n., 18016 Granada, Spain
4
Cancer Registry of Granada, Andalusian School of Public Health, Carretera del Observatorio 4, 18011 Granada, Spain
*
Authors to whom correspondence should be addressed.
†
Co-senior authors.
Nutrients 2023, 15(4), 823; https://doi.org/10.3390/nu15040823
Submission received: 2 January 2023 / Revised: 1 February 2023 / Accepted: 2 February 2023 / Published: 5 February 2023
(This article belongs to the Special Issue Nutrigenetics in Disease Prevention: Mechanistic Pathways and Risk Biomarkers)
Browse Figure
Versions Notes

Abstract

:
Asthma is a chronic non-communicable disease that affects all age groups. The main challenge this condition poses is its heterogeneity. The role of vitamin D in asthma has aroused great interest, correlating low vitamin D levels and polymorphisms in the genes involved in its metabolic pathway with the risk of asthma. The aim of this study was to evaluate the influence of 13 single nucleotide polymorphisms (SNPs) related to the vitamin D metabolism on the susceptibility to asthma. An observational case-control study was performed, including 221 patients with asthma and 442 controls of Caucasian origin from southern Spain. The SNPs CYP24A1 (rs6068816, rs4809957), CYP27B1 (rs10877012, rs4646536, rs703842, rs3782130), GC (rs7041), CYP2R1 (rs10741657) and VDR (ApaI, BsmI, FokI, Cdx2, TaqI) were analyzed by real-time PCR, using TaqMan probes. The logistic regression model adjusted for body mass index revealed that in the genotype model, carriers of the Cdx2 rs11568820-AA genotype were associated with a higher risk of developing asthma (p = 0.005; OR = 2.73; 95% CI = 1.36–5.67; AA vs. GG). This association was maintained in the recessive model (p = 0.004). The haplotype analysis revealed an association between the ACTATGG haplotype and higher risk of asthma for the rs1544410, rs7975232, rs731236, rs4646536, rs703842, rs3782130 and rs10877012 genetic polymorphisms (p = 0.039). The other SNPs showed no effect on risk of developing asthma. The Cdx2 polymorphism was significantly associated with the susceptibility of asthma and could substantially act as a predictive biomarker of the disease.

1. Introduction

Asthma is a chronic inflammatory disease of the airways whose physiological response is bronchial hyperreactivity and that clinically takes the form of repeated episodes of dyspnea, wheezing and flare-ups. These episodes are usually associated with airflow obstruction, partially or totally reversible spontaneously or with specific treatment [1].
Asthma is a chronic non-communicable disease that affects all age groups. According to the Global Burden of Disease study 2015, the global prevalence of asthma increased by 12.6% from 1990 to 2015 [2]. It is estimated that 300 million people worldwide suffer from asthma, and it is the most common chronic disease, responsible for significant morbidity and mortality [3]. The exponential growth in asthma diagnosis in recent decades, followed by the World Health Organization’s estimate of 100 million additional asthmatics by 2025, make it a worldwide public health problem [4].
The main challenge this condition poses is its heterogeneity. Numerous types of risk factors positively associated with the presence of the asthmatic syndrome can be distinguished: host factors (rhinitis, bronchial hyperresponsiveness, obesity, atopy), perinatal factors (preeclampsia, prematurity, smoking during pregnancy, caesarean section, mother’s diet), environmental factors (allergens, tobacco, pollution), medications and genetic factors [5].
Vitamin D function in asthma has aroused great interest, correlating low vitamin D levels and polymorphisms in the genes involved in its metabolic pathway with the risk of asthma [6,7]. Vitamin D and its receptor (VDR) have immunomodulatory and anti-inflammatory properties, dampening the effects of the immune response, both innate and adaptive, due to their effect on dendritic cells, macrophages and T lymphocytes (CD4 + CD8) [8]. Vitamin D also acquires an important role in airway remodeling through changes in epithelial cells and alveolar macrophages and transcription of pro-inflammatory cytokines [3,8]. The active isoform of vitamin D, 1α,25-Dihydroxyvitamin D3 (1,25(OH)2D3), has a direct effect on the development of helper (Th) cells, inhibiting Th1 and augmenting Th2 cell development, which entails an increase in IL-4, IL-5 and IL-10 production [9]. Moreover, the gene that codes for the vitamin D binding protein (GC) has also been described as a factor in susceptibility to developing asthma [7].
Vitamin D has a complex metabolism with enzymes that regulate its active (1,25(OH)2D) and inactive (25(OH)D) forms and its catabolism. Various cytochrome P450 (CYP) enzymes are responsible for the balance between the inactive and active forms of vitamin D: CYP2R1 (25-hydroxylase), responsible for the first hydroxylation that leads to the inactive form 25(OH)D, CYP27B1 (1-α-hydroxylase), which generates 1,25(OH)2D through its 1-hydroxylase activity, and CYP24A1 (24-hydroxylase), which catalyzes both 25(OH)D and 1,25(OH)2D. The 1,25(OH)2D, is a secosteroid hormone which acts as a ligand by selectively binding to the VDR receptor, a transcription factor which binds to DNA sites called vitamin D response elements (VDREs). There are thousands of VDREs regulating hundreds of genes specifically for each cell [10,11,12,13,14]. In this conceptual framework, vitamin D plays an important role in the inflammatory response and the development of the Th2 phenotype, typical of asthmatic disease.
The VDR gene is highly polymorphic. It is located at chromosome 12q13.11 and numerous extensively studied single-nucleotide polymorphisms (SNPs) have been described for it, including ApaI (rs7975232, intron 8, 64978 C > A), BsmI (rs1544410, intron 8, 63980 G > A), TaqI (rs731236, exon 9, 65058 T > C) FokI (rs2228570, exon 2, 30920 C > T) and Cdx2 (rs11568820, intron 1, +1270 G > A) [15,16,17]. BsmI, ApaI and TaqI can modify the expression of the VDR gene without producing a structural change in the protein, due to their position in the three prime untranslated region (3′ UTR), which is related to the stability of the mRNA of VDR [10,18,19]. FokI is located in the start codon, producing a change from thymine to cytosine, and this results in two different translation initiation sites, generating two variants of the VDR protein, one long and the other short [20]. The FokI SNP is associated with variations in vitamin D levels, indicating important consequences in its metabolism [18,21]. The GC gene, which shows a high degree of polymorphism, is at chromosome 4q13, with an SNP characteristically associated with asthma (rs7041) in codon 420 [7].
Vitamin D precursors need to be hydroxylated in order to be activated. Firstly, a hydroxylation takes place at position 25 in the liver, performed by the CYP2R1 or 25-hydroxylase enzyme (encoded by the gene CYP2R1). As a result of this reaction, calcidiol is obtained [22,23]. The second hydroxylation needed to activate vitamin D takes place in the kidney, by means of the CYP27B1 or 1-α-hydroxylase enzyme [24,25]. Finally, the vitamin D molecule is inactivated by the CYP24A1 or 24-hydroxylase enzyme [26,27].
Previous studies have evaluated the association between these variants of the VDR gene and the risk of suffering from asthma. However, the results are contradictory [7,28,29,30,31,32,33,34,35,36,37].
Taking the background presented into consideration, we conducted this study with the aim of evaluating the effects of SNPs in the genes involved in the vitamin D pathway (CYP27B1, CYP24A1, GC and CYP2R1) and in the gene encoding its receptor, VDR (ApaI, BsmI, FokI, TaqI and Cdx2), on the risk of developing asthma.

2. Materials and Methods

We conducted an observational case-control study.

2.1. Study Subjects

This study, with a case/control ratio 1:2, included 221 patients with asthma and 442 controls of Caucasian origin from southern Spain. The cases were recruited at the Hospital Universitario Virgen de las Nieves (Granada, Spain) from March 2013 to April 2022. The controls were individuals over the age of 18 who were recruited at the same hospital and had been living in the same geographical area, with no personal history of asthma.
This case-control study was approved by the Ethics Committee of the Sistema Andaluz de Salud (Andalusian Health Service) and conducted in accordance with the Declaration of Helsinki (code: 2112-N-22). An informed consent form for the donation of blood and saliva samples to the biobank was signed by all the subjects participating in the study. The samples received a confidential codification and treatment.

2.2. Socio-Demographic and Clinical Variables

The socio-demographic and clinical data included were sex, age, smoking status, previous COVID-19 infection, body mass index (BMI), allergies, daily dose of inhaled corticosteroids (ICS), need for oral corticosteroids (OCS), lung function, presence of exacerbations and blood eosinophil count. Each individual’s smoking status was defined as follows: active smoker (consumption of 100 cigarettes or more in life and currently smoke), former smoker (consumption of 100 cigarettes or more in life but currently do not smoke) and non-smoker (no cigarette consumption in life or consumption of fewer than 100 cigarettes in life). Individuals were classified by BMI range following the criteria of the Sociedad Española para el Estudio de la Obesidad (Spanish Society for the Study of Obesity): underweight (BMI ≤ 18.5), normal weight (18.5 < BMI < 24.9), overweight (25 < BMI < 29.9), obese (BMI ≥ 30) [38]. The criteria for assessing asthma were based on the Guía Española para el Manejo del Asma (Spanish Asthma Management Guidelines) (GEMA 5.2) and the Global Initiative for Asthma (GINA) [5,39]. Allergies, OCS and exacerbations were evaluated as present or absent (Yes/No) and ICS as milligrams per day. To evaluate lung function the maximum percentage expiratory volume in the first second of forced exhalation (%FEV1) was used, and blood eosinophil count was analyzed as cells per microliter. All sociodemographic and clinical variables mentioned in the cases were collected at the time of diagnosis.

2.3. Genetic Variables

2.3.1. DNA Isolation

The Biobank of the University Hospital Virgen de las Nieves, which is part of the Andalusian Health Service, granted the DNA samples, isolated form saliva or blood. The saliva samples were collected in BD Falcon 50 mL conical tubes (BD, Plymouth, United Kingdom). The blood samples were collected in BD Vacutainer tubes with EDTA K3 as anticoagulant (3 mL). DNA extraction was performed using the QIAamp DNA Mini extraction kit (Qiagen GmbH, Hilden, Germany), following the specifications provided by the manufacturer for purification of DNA from saliva or blood, and stored at −40 °C. NanoDrop 2000 UV spectrophotometer with 280/260 and 280/230 absorbance ratios were used to measure DNA concentration and purity.

2.3.2. Genotyping and Quality Control

The SNPs were determined by real-time polymerase chain reaction (PCR) allelic discrimination assay using TaqMan probes (ABI Applied Biosystems, 7300 Real-Time PCR System, 96 wells), following the manufacturer’s instructions (Table 1). The VDR BsmI (rs1544410), CYP27B1 rs703842 and CYP27B1 rs3782130 polymorphisms were analyzed using a custom assay by ThermoFisher Scientific (Waltham, MA, United States), coded as AN324M4, ANH6J3F and ANGZRHH, respectively. Sanger sequencing was used in ten percent of the samples to confirm the results obtained. Sanger sequencing and Real-time PCR were performed in the Pharmacogenetics Unit of the Hospital Universitario Virgen de las Nieves. The criteria for SNP quality control were: (1) missing genotype rate per SNP < 0.05, (2) minor allele frequency > 0.01, (3) p value > 0.05 in Hardy-Weinberg equilibrium test and (4) missing genotype rate between cases and controls < 0.05.

2.3.3. Statistical Analysis

The cases and controls were paired based on sex and age using the propensity score matching method (1:2) [40]. The quantitative variables were expressed as the mean (±standard deviation) for those that complied with normality and as the median and percentiles (25th and 75th) for the variables that did not follow a normal distribution. Normality was confirmed with the Kolmogorov–Smirnov test.
We determined the Hardy–Weinberg equilibrium, the haplotype frequencies and the linkage disequilibrium (LD) through the D’ and r2 coefficients. The bivariate analysis of association between the risk of asthma and the polymorphisms was performed with multiple models (genotypic, recessive, dominant, allelic and additive) using the Pearson χ2 test and the Fisher exact test to calculate the odds ratio (OR) and the 95% confidence interval (CI). The models were defined by Purcell et al. in the PLINK tool set [41]. The Bonferroni correction was used for multiple comparisons. We considered unconditional multiple logistic regression models (genotypic, recessive and dominant) to determine the influence of possible confounding variables on the risk of suffering from asthma. The multivariate logistic regression model was performed including all the variables that were significant in the bivariate logistic regression model. The final model was adjusted only with the variables that maintained statistical significance. All the tests were 2-sided, with a significance level of p < 0.05, and were carried out using PLINK and the R 4.2.0 statistical program [41,42]. Linkage disequilibrium was performed with Haploview 4.2 software and the haplotype analysis with SNPStats [43,44].

3. Results

3.1. Patient Characteristics

A total of 663 individuals of Caucasian origin were included in the study: 221 asthma cases and 442 controls. Their socio-demographic, clinical and pathological characteristics are described in Table 2.
In the group of cases, the median age was 56 (46,66) years and 66.5% (147/221) were women. With regard to smoking status, 71.5% (158/221) were non-smokers, 22.6% (50/221) former smokers and 5.9% (13/221) smokers. Most of the patients were obese or overweight, 41.1% (86/209) and 37.8% (79/209), respectively. The control group had a median age of 60 (51,67) years and 62.2% (275/442) were women. A total of 51.4% (225/442) had never smoked, 21.7% (95/442) were former smokers and 29.9% (118/442) were current smokers. As for BMI, a high percentage were overweight, 36.2% (113/313), and 30.8% (96/313) of patients were obese. A total of 8.3% (34/412) had had COVID before the study.
There were statistically significant differences between the cases and the controls with regard to smoking status (p < 0.001; OR = 0.16; 95% CI = 0.08–0.28; Current smoker vs. non-smoker and p < 0.001; OR = 0.75; 95% CI = 0.50–1.11; Former smoker vs non-smoker), BMI (p = 0.006; OR = 2.1; 95% CI = 1.33–3.33; obese vs normal weight and p = 0.006; OR = 1.64; 95% CI = 1.04–2.59; overweight vs normal weight), No statistically significant differences were observed in sex (p = 0.278), age (p = 0.091) and COVID-19 (p = 0.963).

3.2. Genotype Distribution

The observed genotype frequencies were in line with the expected values according to the Hardy-Weinberg equilibrium, except CYP24A1 rs4809957 for the control group (p = 0.034, Table S1). No statistical differences were found from those described in the Iberian population for this variant (CYP24A1 rs4809957 allele G: 0.224 vs. 0.215; p = 0.987) [45]. The D’ and r2 LD values are shown in Table S2 and Figure 1 shows the LD graph. The following pairs of polymorphisms showed strong linkage disequilibrium: CYP27B1 rs4646536/rs3782130 (r2 = 0.80826; D’ = 0.92497), CYP27B1 rs4646536/rs10877012 (r2 = 0.67365; D’ = 0.86887), CYP27B1 rs4646536/rs703842 (r2 = 0.75451; D’ = 0.87413), CYP27B1 rs3782130/rs10877012 (r2 = 0.70678; D’ = 0.87413) and CYP27B1 rs3782130/rs703842 (r2 = 0.79847; D’ = 0.90819). All the polymorphisms showed a minor allele frequency greater than 1%, and therefore none of them was excluded for the analysis (Table S3). The estimated haplotype frequencies are presented in Table S4.

3.3. Influence of Gene Polymorphisms on the Risk of Asthma

The bivariate analysis was performed taking account of the genotypic, dominant, recessive, additive and allelic, models for all the polymorphisms and the risk of developing asthma (Table S5). The VDR Cdx2 (rs11568820) gene polymorphism was the only one that showed a significant association for the genotypic (p = 0.004), recessive (p < 0.001), allelic (p = 0.045) and additive (p = 0.044) models (Table S5). After correction by the Bonferroni method, the genotypic (p = 0.039) and recessive (p = 0.011) models maintained a significant association with the risk of developing asthma (Table S5). For the genotypic model, patients carrying the VDR Cdx2 (rs11568820) AG genotype showed a higher risk of developing asthma (pBonferroni = 0.039; OR = 2.76; 95% CI = 1.46–5.29, AG vs. GG, Table 3). Similarly, carriers of the VDR Cdx2 (rs11568820) AA genotype also showed a higher risk of developing asthma (pBonferroni = 0.039; OR = 2.67; 95% CI = 1.43–5.04, AA vs. GG, Table 3). Likewise, for the recessive model, carriers of the VDR Cdx2 (rs11568820) AA genotype showed a higher risk of suffering from asthma (pBonferroni = 0.011; OR = 2.71; 95% CI = 1.48–5.02, AA vs. G, Table 3). The logistic regression model adjusted for BMI maintained the association obtained for the genotypic model (p = 0.005; OR = 2.73; 95% CI = 1.36–5.67; AA vs. GG, Table 4) and the recessive model (p = 0.004; OR = 2.73; 95% CI = 1.39–5.57; AA vs. G, Table 4). In the other polymorphisms studied, no statistically significant associations were found between any of the models analyzed and the risk of asthma (Table S5). A haplotype analysis was performed for the polymorphisms found to be in strong linkage disequilibrium (Table 5), revealing an association between the ACTATGG haplotype and increased risk of asthma for the rs1544410, rs7975232, rs731236, rs4646536, rs703842, rs3782130 and rs10877012 polymorphisms (p = 0.039; OR = 2.84; 95% CI = 1.06–7.64, Table 5).

4. Discussion

Asthma is a complex disease of multifactorial pathogenesis with marked inflammatory activity, involving Th2 cells, as well as type 2 innate lymphoid cells (ILC2) which release proinflammatory cytokines [5,46]. Vitamin D has been related to several cell processes, such as cell proliferation and differentiation, inflammation, apoptosis, etc., and especially immune system regulatory function, due to the presence of the enzymes needed for its synthesis and that of its receptor in macrophages, dendritic cells, monocytes, T and B cells and structural epithelial cells. These elements are essential parts of the immune system in its protective mission at pulmonary level [23,24,47,48]. Previous studies have discovered a genetic correlation between polymorphisms in the vitamin D metabolic pathway and asthma, due to the start of inflammatory processes and deregulation of the immune system, mainly in a pediatric population [6,7,49,50,51]. Our study was carried out in order to ascertain the influence of eight genetic polymorphisms located in the main genes that regulate vitamin D metabolism (CYP24A1, GC, CYP27B1 and CYP2R1) and five SNPs in the gene that encodes its receptor (VDR) on the susceptibility to asthma, in a Caucasian population in southern Spain.
One of the most studied genes because of its immunomodulatory and anti-inflammatory properties is the vitamin D receptor gene [8,52]. Various studies have found a relationship between the activity of VDR and the presence, differentiation and functionality of T cells [53]. The presence of single nucleotide polymorphisms in the vitamin D receptor gene (VDR) may modify its expression, and, consequently, the biological function of vitamin D, influencing the emergence of asthmatic disease [7,9]. Gene polymorphisms in VDR have been extensively studied, the most clinically important being BsmI (rs1544410), Cdx2 (rs11568820), FokI (rs2228570) and TaqI (rs731236). The Cdx2 (rs11568820) polymorphism is located in the promoter region of the 5′ end of the VDR gene and may influence the correct binding of the primer and, consequently, alter the transcription [15,19]. The results of our study show a statistically significant association between the risk of asthma and the presence of the A allele in the VDR Cdx2 (rs11568820) polymorphism (Table 2). There are not yet any studies that positively correlate the Cdx2 polymorphism and asthma in an adult population, but it has been described in a pediatric population and in other respiratory conditions. In line with our results is a study in a mixed pediatric population (n = 60 cases/17 controls, Brazil), which shows a significant association between the presence of the AA genotype in the VDR Cdx2 SNP and developing asthma (p = 0.003; AA vs. G) [54]. A recent cohort study conducted in a mixed population (725 subjects) showed a significant association between the Cdx2 (rs11568820-AA) genotype and the susceptibility to upper respiratory tract infection (p = 0.001; OR = 1.31; 95% CI = 1.12–1.53; AA vs. GG) [55].
The FokI (rs2228570) polymorphism gives rise to a transcription start codon, and the FokI G variant produces a shorter form of protein, which could influence its functionality [17,18,21]. In our study, no association was found between FokI (rs2228570) and developing asthma. This finding is in line with a meta-analysis from 2014 in a mixed population (n = 1997 cases/1868 controls; China, Canada, Iran, Tunisia, Egypt and the United States) and a study in a Caucasian population (n = 110 cases/110 controls) which report no association between the risk of asthma and this polymorphism [56]. However, another recent meta-analysis from 2022, conducted in a mixed pediatric population (n = 1039 cases/894 controls; Egypt, Turkey, Chile, China, Ireland, Greece, Tunisia, Cyprus and the United States), associates the dominant and additive models of the VDR FokI polymorphism with a lower risk of developing asthma (p = 0.004; OR = 0.67; 95% CI = 0.51–0.88; I2 = 11.6%; p(I2) = 0.34; TT + CT vs CC and p = 0.015; OR = 0.63; 95% CI = 0.43–0.92; I2 = 62.7%; p(I2) = 0.03; T vs. C, respectively) [57].
The BsmI (rs1544410) polymorphism may affect the function of VDR in regulating the stability of mRNA and the efficiency of translation of the protein [34,37]. In this study, we found no association between the BsmI polymorphism and the risk of suffering from asthma. In line with our results is the meta-analysis by Zhou et al. (n = 947 cases/1552 controls) and a study in a Caucasian population (n = 110 cases/110 controls), where no association was found between the SNP and asthmatic disease [37,57]. In contrast, the meta-analysis by Tizaoui et al. (n = 823 cases/954 controls) associated the AA genotype with an increased risk of developing asthma (p = 0.017; OR = 2.017; 95% CI = 1.236–3.851; I2 = 67.5%; p(I2) = 0.05; AA vs. GG) [56].
The ApaI (rs7975232) SNP has the potential to alter the regulation of splicing [58]. In agreement with our study are the two meta-analyses, one conducted in a mixed population (n = 1478 cases/1441 controls) and the other in a mixed pediatric population (n = 1217 cases/1753 controls), which did not observe any association between the ApaI SNP and developing asthma [56,57].
The TaqI (rs731236) is a synonymous polymorphism that does not affect the sequence of amino acids, but, being located near the 3′ UTR of mRNA, it may alter the functionality of the protein [58]. In this study, we did not find a statistically significant association between this SNP and the risk of suffering from asthma. Previous studies show contradictory results. The meta-analysis by Tizaoui et al., conducted in a mixed population (n = 1478 cases/1441 controls) showed a significant association between the TaqI C allele and the risk of suffering from asthma (p = 0.04; OR = 1.488; 95% CI = 1.019–2.174; I2 = 30.21%; p(I2) = 0.46; TC vs. CC) [56]. However, the 2022 meta-analysis in a mixed pediatric population (n = 898 cases/1428 controls) associated the presence of the VDR TaqI C allele as a protective factor against the presence of the condition in the additive model (p = 0.022; OR = 0.45; 95% CI = 0.23–0.89; I2 = 55.4%; p(I2) = 0.106; C vs. T) [57].
The GC gene synthesizes the vitamin D binding protein (VDBP). The rs7041 producing a change from thymine to guanine [58,59]. Our study has not demonstrated the existence of a significant association between the GC rs7041 polymorphism and the susceptibility to asthma. However, two studies conducted in Caucasian populations, adult (n = 110 cases/110 controls) and pediatric (n = 96 cases/96 controls), showed that individuals carrying the GG genotype had a higher risk of suffering from asthma (p = 0.014; OR = 2.85; 95% CI = 1.21–5.5; GG vs. TT + TG and p < 0.0001; OR = 10.7; 95% CI = 4.26–26.9; GG vs. TT + GT, respectively) [37,60].
In our study, the presence of CYP2R1 rs10741657 was not related to a higher risk of suffering from asthma. Similarly, previous studies conducted in a Caucasian population (n = 154 cases/154 controls) and a Caucasian pediatric population (n = 1386 cases/1305 controls) did not observe any association between this SNP and the susceptibility to asthma [49,61].
Our study included the rs3782130, rs4646536, rs703842 and rs10877012 polymorphisms in the CYP27B1 gene, which were not associated with the susceptibility to asthma. In line with our findings, a study in a Caucasian population (n = 154 cases/154 controls), mentioned above, found no statistically significant association between CYP27B1 rs108777012 and the risk of asthma [61]. Moreover, a systematic review showed that the rs4646536 and rs703842 polymorphisms are not related to the risk of developing asthma [49]. To date, there are no studies determining that the CYP27B1 rs3782130 polymorphism influences the development of asthma.
The CYP24A1 rs6068816 and rs4809957 polymorphisms have not been related in our study to the risk of developing asthma. There are currently no studies in the literature that evaluate the association of these polymorphisms with the susceptibility to asthma.
The haplotype analysis revealed that the ACTATGG haplotype (p = 0.032; OR = 2.84; 95% CI: 1.06–7.64) for BsmI, ApaI, TaqI, CYP27B1 (rs4646536), CYP27B1 (rs703842), CYP27B1 (rs3782130), CYP27B1 (rs10877012) was associated with a higher risk of asthma. The presence of the TaqI and ApaI polymorphisms in specific haplotypes affects the stability of the mRNA of VDR and the transcription rate and may alter protein expression. In line with this, a cohort study in an Asian pediatric population (n = 143) revealed that the CA haplotype of VDR rs7975232/rs1544410 was associated with greater susceptibility to bronchial asthma [16].
The main limitation of this study is the small sample size compared to other available studies. This may have prevented us from detecting certain associations. However, the logistic regression analysis, where the effect described for the VDR Cdx2 (rs11568820) polymorphism on the risk of developing asthma was maintained, made it possible to avoid false positive associations. Another limitation of the study is that there is little information to be found in Caucasian and adult populations; most of the studies in which the presence of the polymorphisms studied is related to the risk of asthma are in Asian and paediatric populations. On the other hand, the strengths of our study lie in the homogeneity of the group of cases, composed of patients with asthma recruited in the same geographical area, as well as the homogeneity between cases and controls, which facilitates comparison between the groups.
Further studies that include a wider range of polymorphisms are needed and samples with a larger number of participants of Caucasian origin will be required to confirm or rule out the influence of these genes on the risk of developing asthma.

5. Conclusions

The Cdx2 (rs11568820) polymorphism was significantly associated with the susceptibility to asthma. No association was found with the other polymorphisms of the VDR gene, ApaI (rs7975232), BsmI (rs1544410), FokI (rs2228570) and TaqI (rs731236), nor with the polymorphisms studied in genes involved in vitamin D pathway: CYP24A1 (rs4809957, rs6068816), CYP2R1 (rs10741657), GC (rs7041) and CYP27B1 (rs703842, rs4646536, rs10877012, rs3782130).

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/nu15040823/s1, Table S1: Hardy-Weinberg equilibrium; Table S2: Linkage disequilibrium; Table S3: Minor allele frequencies of SNPs; Table S4: Estimation of haplotype frequencies; Table S5: Polymorphisms and association with risk of asthma.

Author Contributions

Conceptualization, S.R.-T., C.M.-G. and C.P.-R.; methodology, S.R.-T., L.E.P.-L. and J.M.G.-N.; software, S.R.-T. and L.E.P.-L.; validation, C.P.-R. and C.M.-G.; formal analysis, S.R.-T. and J.A.S.-M.; investigation, S.R.-T., L.E.P.-L., J.M.G.-N., A.F.-A. and M.V.G.-G.; resources, A.J.-M.; data curation, C.P.-R., J.A.S.-M. and M.V.G.-G.; writing—original draft preparation, S.R.-T., L.E.P.-L. and J.M.G.-N.; writing—review and editing, C.P.-R., A.J.-M. and C.M.-G.; visualization, C.P.-R. and A.J.-M.; supervision, C.M.-G.; project administration, A.J.-M.; funding acquisition, A.J.-M. All authors have read and agreed to the published version of the manuscript.

Funding

ERDF funds (EU) from the Instituto de Salud Carlos III (PT13/0010/0039) supported by co-funding grants from the Biobank of the Hospital Universitario Virgen de las Nieves.

Institutional Review Board Statement

This study was conducted in accordance with the guidelines of the Declaration of Helsinki and approved by the Ethics and Research Committee of the Sistema Andaluz de Salud (code: 0201-N-23).

Informed Consent Statement

All subjects involved in the study signed the written informed consent form.

Data Availability Statement

Not applicable.

Acknowledgments

The results of this research are part of the doctoral thesis that will be presented by Susana Rojo Tolosa at the University of Granada as part of the doctoral studies in “Pharmacy”.

Conflicts of Interest

The authors declare that there is no conflict of interest that could be perceived as prejudicial to the impartiality of the research conducted, and that there are no financial interest in relation to the work described in this article.

References

  1. Padem, N.; Saltoun, C. Classification of Asthma. Allergy Asthma Proc. 2019, 40, 385–388. [Google Scholar] [CrossRef]
  2. Soriano, J.B.; Abajobir, A.A.; Abate, K.H.; Abera, S.F.; Agrawal, A.; Ahmed, M.B.; Aichour, A.N.; Aichour, I.; Aichour, M.T.E.; Alam, K.; et al. Global, Regional, and National Deaths, Prevalence, Disability-Adjusted Life Years, and Years Lived with Disability for Chronic Obstructive Pulmonary Disease and Asthma, 1990–2015: A Systematic Analysis for the Global Burden of Disease Study 2015. Lancet Respir. Med. 2017, 5, 691–706. [Google Scholar] [CrossRef]
  3. Stern, J.; Pier, J.; Litonjua, A.A. Asthma Epidemiology and Risk Factors. Semin. Immunopathol. 2020, 42, 5–15. [Google Scholar] [CrossRef] [PubMed]
  4. Kuruvilla, M.E.; Vanijcharoenkarn, K.; Shih, J.A.; Lee, F.E.-H. Epidemiology and Risk Factors for Asthma. Respir. Med. 2019, 149, 16–22. [Google Scholar] [CrossRef] [PubMed]
  5. Luzán 5 Health Consulting, S.A. Gema 5.2. Guía Española Para el Manejo del Asma. Madrid, Spain. 2020. Available online: https://www.todostuslibros.com/libros/gema-5-0-guia-espanola-para-el-manejo-del-asma_978-84-17372-97-2 (accessed on 2 January 2023).
  6. Han, Y.-Y.; Forno, E.; Celedón, J.C. Vitamin D Insufficiency and Asthma in a US Nationwide Study. J. Allergy Clin. Immunol. Pract. 2017, 5, 790–796.e1. [Google Scholar] [CrossRef]
  7. Li, F.; Jiang, L.; Willis-Owen, S.A.; Zhang, Y.; Gao, J. Vitamin D Binding Protein Variants Associate with Asthma Susceptibility in the Chinese Han Population. BMC Med. Genet. 2011, 12, 103. [Google Scholar] [CrossRef] [PubMed]
  8. Hall, S.C.; Agrawal, D.K. Vitamin D and Bronchial Asthma: An Overview of Data From the Past 5 Years. Clin. Ther. 2017, 39, 917–929. [Google Scholar] [CrossRef] [PubMed]
  9. Boonstra, A.; Barrat, F.J.; Crain, C.; Heath, V.L.; Savelkoul, H.F.J.; O’Garra, A. 1α,25-Dihydroxyvitamin D3 Has a Direct Effect on Naive CD4+ T Cells to Enhance the Development of Th2 Cells. J. Immunol. 2001, 167, 4974–4980. [Google Scholar] [CrossRef] [PubMed]
  10. Jurutka, P.W.; Whitfield, G.K.; Hsieh, J.C.; Thompson, P.D.; Haussler, C.A.; Haussler, M.R. Molecular Nature of the Vitamin D Receptor and Its Role in Regulation of Gene Expression. Rev. Endocr. Metab. Disord. 2001, 2, 203–216. [Google Scholar] [CrossRef] [PubMed]
  11. Pineda Lancheros, L.E.; Rojo Tolosa, S.; Gálvez Navas, J.M.; Martínez Martínez, F.; Sánchez Martín, A.; Jiménez Morales, A.; Pérez Ramírez, C. Effect of Single Nucleotide Polymorphisms in the Vitamin D Metabolic Pathway on Susceptibility to Non-Small-Cell Lung Cancer. Nutrients 2022, 14, 4668. [Google Scholar] [CrossRef]
  12. González Rojo, P.; Pérez Ramírez, C.; Gálvez Navas, J.M.; Pineda Lancheros, L.E.; Rojo Tolosa, S.; Ramírez Tortosa, M.C.; Jiménez Morales, A. Vitamin D-Related Single Nucleotide Polymorphisms as Risk Biomarker of Cardiovascular Disease. Int. J. Mol. Sci. 2022, 23, 8686. [Google Scholar] [CrossRef]
  13. Díez, B.C.; Pérez-Ramírez, C.; del Mar Maldonado-Montoro, M.; Carrasco-Campos, M.I.; Martín, A.S.; Lancheros, L.E.P.; Martínez Martínez, F.; Calleja-Hernández, M.A.; Ramírez-Tortosa, M.C.; Jiménez-Morales, A. Association between polymorphisms in the vitamin D receptor and susceptibility to multiple sclerosis. Pharm. Genom. 2021, 31, 40–47. [Google Scholar] [CrossRef]
  14. Márquez-Pete, N.; Pérez-Ramírez, C.; Maldonado Montoro, M.D.M.; Martínez-Martínez, F.; Fernández-Llimos, F.; Sánchez-Pozo, A.; Ramírez-Tortosa, M.C.; Jiménez-Morales, A. Association of Vitamin D Receptor Gene Polymorphisms with Rheumatoid Arthritis. 2020. Available online: https://www.archivesofmedicalscience.com/Association-of-vitamin-D-receptor-gene-polymorphisms-nwith-rheumatoid-arthritis,116606,0,2.html (accessed on 2 January 2023).
  15. Bai, Y.H.; Lu, H.; Hong, D.; Lin, C.C.; Yu, Z.; Chen, B.C. Vitamin D Receptor Gene Polymorphisms and Colorectal Cancer Risk: A Systematic Meta-Analysis. World J. Gastroenterol. 2012, 18, 1672–1679. [Google Scholar] [CrossRef]
  16. Zhang, Y.-J.; Zhang, L.; Chen, S.-Y.; Yang, G.-J.; Huang, X.-L.; Duan, Y.; Yang, L.-J.; Ye, D.-Q.; Wang, J. Association between VDR Polymorphisms and Multiple Sclerosis: Systematic Review and Updated Meta-Analysis of Case-Control Studies. Neurol. Sci. 2018, 39, 225–234. [Google Scholar] [CrossRef] [PubMed]
  17. Miyamoto, K.-I.; Kesterson, R.A.; Yamamoto, H.; Taketani, Y.; Nishiwaki, E.; Tatsumi, S.; Inoue, Y.; Morita, K.; Takeda, E.; Pike, J.W. Structural Organization of the Human Vitamin D Receptor Chromosomal Gene and Its Promoter. Mol. Endocrinol. 1997, 11, 1165–1179. [Google Scholar] [CrossRef] [PubMed]
  18. Kerr Whitfield, G.; Remus, L.S.; Jurutka, P.W.; Zitzer, H.; Oza, A.K.; Dang, H.T.L.; Haussler, C.A.; Galligan, M.A.; Thatcher, M.L.; Dominguez, C.E.; et al. Functionally Relevant Polymorphisms in the Human Nuclear Vitamin D Receptor Gene. Mol. Cell. Endocrinol. 2001, 177, 145–159. [Google Scholar] [CrossRef] [PubMed]
  19. Pulito, C.; Terrenato, I.; Di Benedetto, A.; Korita, E.; Goeman, F.; Sacconi, A.; Biagioni, F.; Blandino, G.; Strano, S.; Muti, P.; et al. Cdx2 polymorphism affects the activities of vitamin D receptor in human breast cancer cell lines and human breast carcinomas. PLoS ONE 2015, 10, e0124894. [Google Scholar] [CrossRef] [PubMed]
  20. Rochel, N. Vitamin D and Its Receptor from a Structural Perspective. Nutrients 2022, 14, 2847. [Google Scholar] [CrossRef] [PubMed]
  21. Agnello, L.; Scazzone, C.; Ragonese, P.; Salemi, G.; Lo Sasso, B.; Schillaci, R.; Musso, G.; Bellia, C.; Ciaccio, M. Vitamin D Receptor Polymorphisms and 25-Hydroxyvitamin D in a Group of Sicilian Multiple Sclerosis Patients. Neurol. Sci. 2016, 37, 261–267. [Google Scholar] [CrossRef]
  22. Cheng, J.B.; Levine, M.A.; Bell, N.H.; Mangelsdorf, D.J.; Russell, D.W. Genetic Evidence That the Human CYP2R1 Enzyme Is a Key Vitamin D 25-Hydroxylase. Proc. Natl. Acad. Sci. USA 2004, 101, 7711–7715. [Google Scholar] [CrossRef] [Green Version]
  23. Pineda Lancheros, L.E.; Pérez Ramírez, C.; Sánchez Martín, A.; Gálvez Navas, J.M.; Martínez Martínez, F.; Ramírez Tortosa, M.D.C.; Jiménez Morales, A. Impact of Genetic Polymorphisms on the Metabolic Pathway of Vitamin D and Survival in Non-Small Cell Lung Cancer. Nutrients 2021, 13, 3783. [Google Scholar] [CrossRef] [PubMed]
  24. Toledano, J.M.; Moreno-Fernandez, J.; Puche-Juarez, M.; Ochoa, J.J.; Diaz-Castro, J.; Toledano, J.M.; Moreno-Fernandez, J.; Puche-Juarez, M.; Ochoa, J.J.; Diaz-Castro, J. Implications of Vitamins in COVID-19 Prevention and Treatment through Immunomodulatory and Anti-Oxidative Mechanisms. Antioxidants 2021, 11, 5. [Google Scholar] [CrossRef] [PubMed]
  25. Takeyama, K.I.; Kitanaka, S.; Sato, T.; Kobori, M.; Yanagisawa, J.; Kato, S. 25-Hydroxyvitamin D3 1alpha-Hydroxylase and Vitamin D Synthesis. Science 1997, 277, 1827–1830. [Google Scholar] [CrossRef] [PubMed]
  26. Ohyama, Y.; Noshiro, M.; Okuda, K. Cloning and Expression of CDNA Encoding 25-Hydroxyvitamin D3 24-Hydroxylase. FEBS Lett. 1991, 278, 195–198. [Google Scholar] [CrossRef]
  27. Latacz, M.; Snarska, J.; Kostyra, E.; Fiedorowicz, E.; Savelkoul, H.F.J.; Grzybowski, R.; Cieślińska, A. Single Nucleotide Polymorphisms in 25-Hydroxyvitamin D3 1-Alpha-Hydroxylase (CYP27B1) Gene: The Risk of Malignant Tumors and Other Chronic Diseases. Nutrients 2020, 12, 801. [Google Scholar] [CrossRef]
  28. Awasthi, N.; Awasthi, S.; Pandey, S.; Gupta, S. Association of Vitamin D Receptor Gene Polymorphisms in North Indian Children with Asthma: A Case-Control Study. Int. J. Mol. Epidemiol. Genet. 2021, 12, 24. [Google Scholar]
  29. Raby, B.A.; Lazarus, R.; Silverman, E.K.; Lake, S.; Lange, C.; Wjst, M.; Weiss, S.T. Association of Vitamin D Receptor Gene Polymorphisms with Childhood and Adult Asthma. Am. J. Respir. Crit. Care Med. 2004, 170, 1057–1065. [Google Scholar] [CrossRef]
  30. Despotovic, M.; Jevtovic Stoimenov, T.; Stankovic, I.; Basic, J.; Pavlovic, D. Vitamin D Receptor Gene Polymorphisms in Serbian Patients With Bronchial Asthma: A Case-Control Study. J. Cell. Biochem. 2017, 118, 3986–3992. [Google Scholar] [CrossRef]
  31. Rodrigues Simões, T.M.; Da Silva, R.; Bianco, B.; Fonseca, F.L.A.; Solé, D.; Oselka Saccardo Sarni, R. Vitamin D Levels, Frequency of Vitamin D Receptor Gene Polymorphisms, and Associations with Overweight and Asthma in Brazilian Schoolchildren. Ann. Nutr. Metab. 2019, 75, 238–245. [Google Scholar] [CrossRef]
  32. Leiter, K.; Franks, K.; Borland, M.L.; Coleman, L.; Harris, L.; Le Souëf, P.N.; Laing, I.A. Vitamin D Receptor Polymorphisms Are Associated with Severity of Wheezing Illnesses and Asthma Exacerbations in Children. J. Steroid Biochem. Mol. Biol. 2020, 201, 105692. [Google Scholar] [CrossRef]
  33. Galvão, A.A.; De Araújo Sena, F.; Andrade Belitardo, E.M.M.D.; De Santana, M.B.R.; Costa, G.N.D.O.; Cruz, Á.A.; Barreto, M.L.; Costa, R.D.S.; Alcantara-Neves, N.M.; Figueiredo, C.A. Genetic Polymorphisms in Vitamin D Pathway Influence 25(OH)D Levels and Are Associated with Atopy and Asthma. Allergy Asthma. Clin. Immunol. 2020, 16, 62. [Google Scholar] [CrossRef] [PubMed]
  34. Bossé, Y.; Lemire, M.; Poon, A.H.; Daley, D.; He, J.Q.; Sandford, A.; White, J.H.; James, A.L.; Musk, A.W.; Palmer, L.J.; et al. Asthma and Genes Encoding Components of the Vitamin D Pathway. Respir. Res. 2009, 10, 98. [Google Scholar] [CrossRef] [PubMed]
  35. Saadi, A.; Gao, G.; Li, H.; Wei, C.; Gong, Y.; Liu, Q. Association Study between Vitamin D Receptor Gene Polymorphisms and Asthma in the Chinese Han Population: A Case-Control Study. BMC Med. Genet. 2009, 10, 71. [Google Scholar] [CrossRef]
  36. Wjst, M. Variants in the Vitamin D Receptor Gene and Asthma. BMC Genet. 2005, 6, 2. [Google Scholar] [CrossRef]
  37. Nasiri-Kalmarzi, R.; Abdi, M.; Hosseini, J.; Tavana, S.; Mokarizadeh, A.; Rahbari, R. Association of Vitamin D Genetic Pathway with Asthma Susceptibility in the Kurdish Population. J. Clin. Lab. Anal. 2020, 34, e23039. [Google Scholar] [CrossRef]
  38. Rubio Hererra, M.A.; Salas-Salvadó, J.; Barbany, M.; Moreno, B.; Aranceta, J.; Bellido, D.; Blay, V.; Carraro, R.; Formiguera, X.; Foz, M.; et al. Consenso SEEDO 2007 Para La Evaluación Del Sobrepeso y La Obesidad y El Establecimiento de Criterios de Intervención Terapéutica. Med. Clin. 2007, 128, 184–196. [Google Scholar] [CrossRef]
  39. GINA. Global Iniciative for Asthma Management and Prevention (GINA 2019); GINA: Fontana, WI, USA, 2019. [Google Scholar]
  40. Randolph, J.J.; Falbe, K.; Manuel, A.K.; Balloun, J.L. A Step-by-Step Guide to Propensity Score Matching in R. Pract. Assess. Res. Eval. 2019, 19, 18. [Google Scholar] [CrossRef]
  41. Purcell, S.; Neale, B.; Todd-Brown, K.; Thomas, L.; Ferreira, M.A.R.; Bender, D.; Maller, J.; Sklar, P.; De Bakker, P.I.W.; Daly, M.J.; et al. PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage Analyses. Am. J. Hum. Genet. 2007, 81, 559–575. [Google Scholar] [CrossRef]
  42. Team R.C. R: A Language and Environment for Statistical Computing 4.0.2; R Core Team: Vienna, Austria, 2020. [Google Scholar]
  43. Barrett, J.C.; Fry, B.; Maller, J.; Daly, M.J. Haploview: Analysis and Visualization of LD and Haplotype Maps. Bioinformatics 2005, 21, 263–265. [Google Scholar] [CrossRef] [PubMed]
  44. Solé, X.; Guinó, E.; Valls, J.; Iniesta, R.; Moreno, V. SNPStats: A Web Tool for the Analysis of Association Studies. Bioinformatics 2006, 22, 1928–1929. [Google Scholar] [CrossRef]
  45. Auton, A.; Abecasis, G.R.; Altshuler, D.M.; Durbin, R.M.; Bentley, D.R.; Chakravarti, A.; Clark, A.G.; Donnelly, P.; Eichler, E.E.; Flicek, P.; et al. A Global Reference for Human Genetic Variation. Nature 2015, 526, 68. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Caminati, M.; Pham, D.L.; Bagnasco, D.; Canonica, G.W. Type 2 Immunity in Asthma. World Allergy Organ. J. 2018, 11, 13. [Google Scholar] [CrossRef] [PubMed]
  47. Bikle, D.D. Vitamin D Metabolism, Mechanism of Action, and Clinical Applications. Chem. Biol. 2014, 21, 319–329. [Google Scholar] [CrossRef]
  48. Sassi, F.; Tamone, C.; D’amelio, P. Vitamin D: Nutrient, Hormone, and Immunomodulator. Nutrients 2018, 10, 1656. [Google Scholar] [CrossRef] [PubMed]
  49. Ashok, N.; Kirubakaran, R.; Saraswathy, R. Association of Vitamin D Gene Polymorphisms in Children with Asthma—A Systematic Review. Heliyon 2020, 6, e04795. [Google Scholar] [CrossRef]
  50. Munkhbayarlakh, S.; Kao, H.F.; Hou, Y.I.; Tuvshintur, N.; Bayar-Ulzii, B.; Narantsetseg, L.; Wang, J.Y.; Hsin Wu, L.S. Vitamin D Plasma Concentration and Vitamin D Receptor Genetic Variants Confer Risk of Asthma: A Comparison Study of Taiwanese and Mongolian Populations. World Allergy Organ. J. 2019, 12, 100076. [Google Scholar] [CrossRef]
  51. Navas-Nazario, A.; Li, F.Y.; Shabanova, V.; Weiss, P.; Cole, D.E.C.; Carpenter, T.O.; Bazzy-Asaad, A. Effect of Vitamin D-Binding Protein Genotype on the Development of Asthma in Children. Ann. Allergy. Asthma Immunol. 2014, 112, 519–524. [Google Scholar] [CrossRef]
  52. Baker, A.R.; McDonnell, D.P.; Hughes, M.; Crisp, T.M.; Mangelsdorf, D.J.; Haussler, M.R.; Pike, J.W.; Shine, J.; O’Malley, B.W. Cloning and Expression of Full-Length CDNA Encoding Human Vitamin D Receptor. Proc. Natl. Acad. Sci. USA 1988, 85, 3294–3298. [Google Scholar] [CrossRef]
  53. Nagpal, S.; Na, S.; Rathnachalam, R. Noncalcemic Actions of Vitamin D Receptor Ligands. Endocr. Rev. 2005, 26, 662–687. [Google Scholar] [CrossRef]
  54. Santos, H.L.B.S.; De Souza E Silva, S.; De Paula, E.; Pereira-Ferrari, L.; Mikami, L.; Riedi, C.A.; Chong-Neto, H.J.; Rosário, N.A. Vitamin D Receptor gene mutations and vitamin D serum levels inasthmatic children. Rev. Paul. Pediatr. 2018, 36, 269. [Google Scholar] [CrossRef]
  55. Jolliffe, D.A.; Greiller, C.L.; Mein, C.A.; Hoti, M.; Bakhsoliani, E.; Telcian, A.G.; Simpson, A.; Barnes, N.C.; Curtin, J.A.; Custovic, A.; et al. Vitamin D Receptor Genotype Influences Risk of Upper Respiratory Infection. Br. J. Nutr. 2018, 120, 891–900. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  56. Tizaoui, K.; Berraies, A.; Hamdi, B.; Kaabachi, W.; Hamzaoui, K.; Hamzaoui, A. Association of Vitamin D Receptor Gene Polymorphisms with Asthma Risk: Systematic Review and Updated Meta-Analysis of Case-Control Studies. Lung 2014, 192, 955–965. [Google Scholar] [CrossRef]
  57. Zhou, Y.; Li, S. Meta-Analysis of Vitamin D Receptor Gene Polymorphisms in Childhood Asthma. Front. Pediatr. 2022, 10, 843691. [Google Scholar] [CrossRef]
  58. Uitterlinden, A.G.; Fang, Y.; Van Meurs, J.B.J.; Pols, H.A.P.; Van Leeuwen, J.P.T.M. Genetics and Biology of Vitamin D Receptor Polymorphisms. Gene 2004, 338, 143–156. [Google Scholar] [CrossRef]
  59. Yang, F.; Bergeron, J.M.; Linehan, L.A.; Lalley, P.A.; Sakaguchi, A.Y.; Bowman, B.H. Mapping and Conservation of the Group-Specific Component Gene in Mouse. Genomics 1990, 7, 509–516. [Google Scholar] [CrossRef] [PubMed]
  60. Fawzy, M.S.; Elgazzaz, M.G.; Ibrahim, A.; Hussein, M.H.; Khashana, M.S.; Toraih, E.A. Association of Group-Specific Component Exon 11 Polymorphisms with Bronchial Asthma in Children and Adolescents. Scand. J. Immunol. 2019, 89, e12740. [Google Scholar] [CrossRef]
  61. Lahmar, O.; Salhi, M.; Kaabachi, W.; Berraies, A.; Ammar, J.; Soomro, M.H.; Larsen, M.; Annesi-Maesano, I.; Hamzaoui, K.; Hamzaoui, A. Association Between Vitamin D Metabolism Gene Polymorphisms and Risk of Tunisian Adults’ Asthma. Lung 2018, 196, 285–295. [Google Scholar] [CrossRef] [PubMed]
Nutrients 15 00823 g001 550
Figure 1. Linkage disequilibrium (LD). Polymorphisms with strong linkage disequilibrium are shown in darker shades and those with less linkage disequilibrium are shown in lighter shades.
Figure 1. Linkage disequilibrium (LD). Polymorphisms with strong linkage disequilibrium are shown in darker shades and those with less linkage disequilibrium are shown in lighter shades.
Nutrients 15 00823 g001
Table
Table 1. Gene polymorphisms and TaqMan ID.
Table 1. Gene polymorphisms and TaqMan ID.
GeneLocation, SNPdbSNP IDAssay ID
VDR
(12q13.11)		Intron 8, C > A rs7975232 (ApaI)C__28977635_10
Intron 8, G > Ars1544410 (BsmI) AN324M4
Exon 2, C > Trs2228570 (FokI)C__12060045_20
Intron 1, G > A rs11568820 (Cdx2) C___2880808_10
Exon 9, T > Crs731236 (TaqI)C___2404008_10
CYP27B1
(12q14.1)		3′ UTR, A > G rs703842ANH6J3F
Promotor 5′, G > Crs3782130ANGZRHH
5′ UTR, A > G
Intron 6, T > C		rs10877012
rs4646536		C__26237740_10
C__25623453_10
CYP24A1
(20q13.2)		Exon 6, G > Ars6068816C__25620091_20
3′ UTR, G > Crs4809957C___3120981_20
CYP2R1
(11p15.2) 		5′ UTR, A > Grs10741657C___2958430_10
GC
(4q13.3)		Exon 11, T > G rs7041C___3133594_30
Table
Table 2. Clinical-pathological characteristics of asthma cases and controls.
Table 2. Clinical-pathological characteristics of asthma cases and controls.
CasesControlsχ²p ValueReferenceOR95% CI
Nn (%)Nn (%)
Gender221 442
Female 147 (66.5) 275 (62.2)1.1770.278
Male 74 (33.5) 167 (37.8)
Age22156 (46, 66)44260 (51, 67) 0.091 *
Smoking status221 442
Current smokers 13 (5.9) 118 (29.9)43.06<0.001Non-smokers0.160.08–0.28
Former smokers 50 (22.6) 95 (21.7)0.750.50–1.11
Non-smokers 158 (71.5) 225 (51.4)1
COVID-19221 412
Yes 18 (8.1) 34 (8.3)0.0020.963
No 203 (91.9) 378 (91.7)
BMI209 313
Normal weight 44 (21.1) 103 (33.0)10.290.006Normal weight1
Overweight 79 (37.8) 113 (36.2)1.641.04–2.59
Obesity 86 (41.1) 96 (30.8)2.11.33–3.33
Allergy (pollen or medications)221
Yes 97 (43.9)
No 124 (56.1)
ICS (mg/day)221
320 (160, 640)
OCS (dose/year)221
Yes 139 (62.9)
No 82 (37.1)
%FEV1191
74.8 ± 23.5
Exacerbations/year218
Yes 78 (35.8)
No 140 (64.2)
Eosinophils (cells/μL)213
280 (120, 560)
Quantitative variables: Normal distribution: mean ± standard deviation. Non-normal distribution: P50 [P25, P75]; Qualitative variables: number (percentage); * p value for t test; N means the whole number of patients considered; n means the number of patients in subgroups; Shade indicates that the t-test value is significant (p < 0.05); ICS: inhaled corticosteroids; BMI: body mass index; OCS: oral corticosteroids; %FEV1: maximum percentage expiratory volume in the first second of forced expiration.
Table
Table 3. Effect of the Cdx2 (rs11568820) polymorphism on susceptibility to asthma.
Table 3. Effect of the Cdx2 (rs11568820) polymorphism on susceptibility to asthma.
ModelsGenotypeCases [n (%)]Controls [n (%)]p-Value aAdjusted
p-Value b		OR cCI 95%
GenotypicGG113 (51.4)232 (54.7)0.0030.0391
AG81 (36.8)172 (40.6)2.761.46–5.29
AA 26 (11.8)20 (4.7)2.671.43–5.04
DominantA107 (48.6)192 (45.3)0.4181
GG113 (51.4)232 (54.7)
RecessiveAA26 (11.8)20 (4.7)<0.0010.0112.711.48–5.02
G194 (88.2)404 (95.3)
AllelicA133 (30.2)212 (25)0.0450.579
G307 (69.8)636 (75)
Additive---0.0440.577
Shade means the value is significant; OR: odds ratio; CI: confidence interval; a p-value for χ2-test; b p-value for Bonferroni correction; c Unadjusted or crude ORs.
Table
Table 4. Impact of clinical characteristics and Cdx2 (rs11568820) polymorphism on susceptibility to asthma.
Table 4. Impact of clinical characteristics and Cdx2 (rs11568820) polymorphism on susceptibility to asthma.
GenotypicDominantRecessiveAdditive
AA vs. GGAG vs. GGA vs. GGAA vs. GA vs. G
p-ValueOR95% CIp-ValueOR95% CIP-ValueOR95% CIp-ValueOR95% CIp-ValueOR95% CI
BMI
Overweight0.0171.761.11–2.800.0171.761.11–2.800.0191.731.10–2.760.0171.761.11–2.800.0011.731.10–2.75
Obese0.0012.171.37–3.480.0012.171.37–3.480.0012.171.37–3.450.0012.171.37–3.480.0202.141.36–3.42
rs115688200.0052.731.36–5.670.9941.000.68–1.460.3671.180.82–1.690.0042.731.39–5.570.0511.321.00–1.75
Shade indicates that the t-test value is significant (p < 0.05).
Table
Table 5. Haplotype association with susceptibility to asthma.
Table 5. Haplotype association with susceptibility to asthma.
rs1544410rs7975232rs731236rs4646536rs703842rs3782130rs10877012Freq.OR (95% CI)p Value
1GCTATGG0.33291.00---
2AACATGG0.23821.02 (0.69–1.50)0.93
3AACGCCT0.1081.30 (0.79–2.15)0.3
4GATATGG0.06291.79 (0.27–1.19)0.14
5GCTGCCT0.06020.63 (0.29–1.35)0.24
6ACTATGG0.0322.84 (1.06–7.64)0.039
7GATGCCT0.02790.77 (0.32–1.84)0.56
8AATATGG0.01391.47 (0.40–5.41)0.56
9GACATGG0.01022.76 (0.45–17.14)0.28
rare*******0.11381.40 (0.89–2.22)0.15
Overall haplotype association p value: 0.031; Freq: haplotype frequency; Shading indicates that the value is significant (p < 0.05); * Reference to rare haplotypes as there is no symbol to identify the group.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Rojo-Tolosa, S.; Pineda-Lancheros, L.E.; Gálvez-Navas, J.M.; Sánchez-Martínez, J.A.; González-Gutiérrez, M.V.; Fernández-Alonso, A.; Morales-García, C.; Jiménez-Morales, A.; Pérez-Ramírez, C. Association between Single Nucleotide Polymorphisms Related to Vitamin D Metabolism and the Risk of Developing Asthma. Nutrients 2023, 15, 823. https://doi.org/10.3390/nu15040823

AMA Style

Rojo-Tolosa S, Pineda-Lancheros LE, Gálvez-Navas JM, Sánchez-Martínez JA, González-Gutiérrez MV, Fernández-Alonso A, Morales-García C, Jiménez-Morales A, Pérez-Ramírez C. Association between Single Nucleotide Polymorphisms Related to Vitamin D Metabolism and the Risk of Developing Asthma. Nutrients. 2023; 15(4):823. https://doi.org/10.3390/nu15040823

Chicago/Turabian Style

Rojo-Tolosa, Susana, Laura Elena Pineda-Lancheros, José María Gálvez-Navas, José Antonio Sánchez-Martínez, María Victoria González-Gutiérrez, Andrea Fernández-Alonso, Concepción Morales-García, Alberto Jiménez-Morales, and Cristina Pérez-Ramírez. 2023. "Association between Single Nucleotide Polymorphisms Related to Vitamin D Metabolism and the Risk of Developing Asthma" Nutrients 15, no. 4: 823. https://doi.org/10.3390/nu15040823

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop